news
Desidustat prevents development of ARDS in Phase II COVID-19 trial
In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).
List view / Grid view
oral therapeutic candidate
news
Positive top line data released for study of C21 in COVID-19 patients
In hospitalised COVID-19 patients, researchers found that C21 reduced the risk of needing oxygen at the end of treatment by 40 percent.
news
Direct eye injections best treat uveitic macular edema: study
Direct eye injections treat uveitic macular edema more effectively than treatments placed adjacent to the eye, reveals new Mount Sinai research...
news
FDA evaluates prescription opioid medications approved for children
The FDA has heard from professional groups, including the American Academy of Paediatrics about the use of opioid cough suppressants for children...
news
$3 million grant given for ALS trials
21 July 2016 | By Niamh Louise Marriott, Digitial Content Producer
Almost $3 million in funding to support a Phase II trial of a new therapeutic approach, developed by Amylyx, for the treatment of ALS...
